Sotera Health Company · NASDAQ:SHC
Sotera Health — Q3 2026 Earnings Presentation
26 slides from Sotera Health's earnings presentation, Nov 3, 2026
Slide 1: Third-Quarter and Year-to-Date 2026 Earnings Results
Safeguarding Global Health® Third-Quarter and Year-to-Date 2026 Earnings Results November 3, 2026 © 2026 Sotera Health Company | All Rights Reserved.
Slide 2: Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures
Cautionary Note Regarding Forward-Looking Statements and Non-GAAP Financial Measures Unless expressly indicated or the context requires otherwise, the terms “Sotera Health,” “Company,” “we,” “us,” and “our” in this presentation refer to Sotera Health Company, a Delaware corporation, and, where appro
Slide 3: Speakers
Speakers Michael B. Petras, Jr. Executive Chairman of the Board Alton Shader Chief Executive Officer Jonathan M. Lyons Senior Vice President and Chief Financial Officer © 2026 Sotera Health Company | All Rights Reserved. 2
Slide 4: Third-Quarter Performance
Third-Quarter Performance “We are pleased with our third-quarter performance, which included solid top- and bottom-line constant currency growth, along with nearly 100 basis points of sequential Adjusted EBITDA margin expansion. Our performance was supported by year-over-year constant currency reven
Slide 5: Q3 2026 Highlights
Q3 2026 Highlights (1) Performance Net Delivered solid top- and bottom-line constant currency growth Revenues 4.4%; 4.4% CC (2)(3) Sequential Adjusted EBITDA margin improved nearly 100bps to 52.5% Sterigenics: 8.2% CC revenue growth; segment income margin improved 57bps Nelson Labs: 9.2% CC
Slide 6: Consolidated Financial Performance
Consolidated Financial Performance $ In millions, except Adjusted EPS and Adjusted EBITDA margin Third Quarter Year-to-Date +4.4% / +4.4% CC +7.7% / +6.3% CC $325 $926 $311 $860 Revenue 2025 2026 2025 2026 +3.9% / +4.0% CC +7.9% / +6.5% CC $171 $471 $164 $437 Adjusted EBITDA 52.7% 52.5% 50.8% 50.9%
Slide 7: Sterigenics Financial Performance
Sterigenics Financial Performance $ In millions Third Quarter Year-to-Date Net Revenues +8.5% / +8.2% CC Net Revenues +8.9% / +7.2% CC Segment Income +9.6% / +9.2% CC Segment Income +9.6% / +7.8% CC $209 $607 $193 $557 $117 $332 $107 $303 55.6% 56.1% 54.3% 54.7% 2025 Revenue Segment Income 2026 2025
Slide 8: Nordion Financial Performance
Nordion Financial Performance $ In millions Third Quarter Year-to-Date Net Revenues -12.4% / -11.5% CC Net Revenues +6.1% / +6.2% CC Segment Income -11.4% / -10.4% CC Segment Income +8.2% / +8.6% CC $146 $63 $138 $55 $79 $85 $38 $34 60.6% 61.3% 57.3% 58.4% 2025 Revenue Segment Income 2026 2025 Reven
Slide 9: Nelson Labs Financial Performance
Nelson Labs Financial Performance $ In millions Third Quarter Year-to-Date Net Revenues +8.8% / +9.2% CC Net Revenues +4.9% / +3.7% CC Segment Income +2.5% / +3.0% CC Segment Income -2.4% / -3.9% CC $61 $165 $173 $56 $19 $19 $55 $54 34.1% 32.1% 33.3% 31.0% 2025 Revenue Segment Income 2026 2025 Reven
Slide 10: Liquidity, Net Leverage and Investments
Liquidity, Net Leverage and Investments $ In millions $937 $1,004 $687 $592 $592 $410 • Continued strong cash and liquidity position Liquidity (1) • No outstanding borrowings on revolving line of credit $277 $345 $412 12/31/24 12/31/25 9/30/26 Unrestricted Cash Revolver Availability 3.7x Net 3.2x 2.
Slide 11: 2026 Outlook
2026 Outlook © 2026 Sotera Health Company | All Rights Reserved. 10
Slide 12: Full-year 2026 Outlook
Full-year 2026 Outlook August 6th Outlook November 3rd Outlook $1,236M to $1,254M $1,233M to $1,250M Net Revenues +6.25% to 7.75% +5.95% to 7.45% +5.25% to 6.75% CC +5.25% to 6.75% CC $634M to $643M $632M to $641M Adjusted EBITDA +6.75% to 8.25% +6.45% to 7.95% +5.75% to 7.25% CC +5.75% to 7.25% CC
Slide 13: Additional 2026 Outlook Items
Additional 2026 Outlook Items (1) • Expect full-year revenue and Adjusted EBITDA foreign exchange benefit of 70 basis points; Q4 foreign currency expected to be a headwind of more than 100 basis points • Full-year Adjusted EBITDA margins approximately flat versus 2025 Outlook Highlights • Total comp
Slide 14: Corporate Overview
Corporate Overview © 2026 Sotera Health Company | All Rights Reserved. 13
Slide 15: Safeguarding Global Health
Safeguarding Global Health® Global customer base in over Over 3,000 associates Provide end-to-end Integrated global network of 50 countries solutions for our customers 63 facilities located in in highly-regulated markets 13 countries Customers include 40+ of top 50 medical device companies, Customer
Slide 16: Our Crucial Role in the Healthcare Supply Chain
Our Crucial Role in the Healthcare Supply Chain R&D, materials Pre-FDA filing tests Product Sterilization Quality control Distribution and packaging and clinical trials manufacturing tests optimization ✓✓ ✓✓ ✓ ✓✓✓ ✓✓ ✓ ✓ ✓ © 2026 Sotera Health Company | All Rights Reserved. 15
Slide 17: Three Integrated Businesses Supporting the Global Healthcare Supply Chain
Three Integrated Businesses Supporting the Global Healthcare Supply Chain Global leader in comprehensive World’s Largest Provider of Global leader in microbiological sterilization solutions Co-60 sealed sources and analytical lab testing 2,000+ Providing 2,000+ customers Customers(1) (1) peace of Pr
Slide 18: Our Company's Key Priorities
Our Company’s Key Priorities 1 2 3 4 Excellence in Win in growth Driving Disciplined serving our markets operational capital customers with excellence to deployment end-to-end enhance free solutions cash flow Strong Execution to Generate Value for Our Stakeholders © 2026 Sotera Health Company | All
Slide 19: Global Leader Positioned for Sustainable Growth
Global Leader Positioned for Sustainable Growth © 2026 Sotera Health Company | All Rights Reserved. 18
Slide 20: Appendix
Appendix © 2026 Sotera Health Company | All Rights Reserved. 19
Slide 21: Non-GAAP Financial Measures
Non-GAAP Financial Measures (unaudited) (dollars in thousands, except per share amounts) Three Months Ended Nine Months Ended September 30, September 30, 2026 2025 2026 2025 Net income $ 58,391 $ 48,400 $ 138,623 $ 43,102 Amortization of intangible assets 5,526 5,648 16,691 36,246 Share-based compen
Slide 22: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) a) Represents share-based compensation expense related to employees and non-employee Directors. b) Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the Term Loans and the Revolving Cr
Slide 23: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) (unaudited) (dollars in thousands) Twelve months Year end December 31, ended September 30, 2024 2025 2026 Net income $ 44,398 $ 77,949 $ 173,470 Amortization of intangible assets 79,377 41,798 22,243 Share-based compensation(a) 36,896 31,068 37,219 Loss on ref
Slide 24: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) a) Represents share-based compensation expense related to employees and Non-Employee Directors. b) Represents the write-off of unamortized debt issuance costs and discounts, as well as certain other costs incurred related to the refinancing activity for the Te
Slide 25: Non-GAAP Financial Measures (continued)
Non-GAAP Financial Measures (continued) (unaudited) (dollars in thousands) As of December 31, As of September 30, 2024 2025 2026 Current portion of long-term debt $ 14,803 $ 13,973 $ 13,933 Long-term debt less current portion 2,208,100 2,126,724 2,123,216 Current portion of finance leases 2,923 3,46
Slide 26: Non-GAAP Financial Measures Definitions
Non-GAAP Financial Measures Definitions • Adjusted Net Income is defined as net income (loss) before amortization and certain other adjustments that we do not consider in our evaluation of our ongoing operating performance from period to period. • Adjusted EBITDA is defined as Adjusted Net Income be
Sotera Health Company — Q3 2026 Earnings Presentation on 6ix